Myxoma virus and oncolytic virotherapy: A new biologic weapon in the war against cancer

Expert Opinion on Biological Therapy

Volumn 7, Issue 9, 2007, Pages 1415-1425

  Stanford, Marianne M ^b   McFadden, Grant ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Akt; mTOR; Oncolysis; Poxvirus; Rapamycin; Virotherapy

Indexed keywords

CYCLOSPORIN; ONCOLYTIC ADENOVIRUS; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; MYXOMA VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; POXVIRUS INFECTION; REVIEW; TUMOR CELL; TUMOR CELL DESTRUCTION; VACCINIA VIRUS; VIROGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; HUMANS; MYXOMA VIRUS; NEOPLASMS; ONCOLYTIC VIROTHERAPY;

ANIMALIA; LAGOMORPHA; MYXOMA VIRUS; ORYCTOLAGUS CUNICULUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 34748903753     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.9.1415     Document Type: Review

References (102)

1. DOCK G: Influence of complicating diseases upon leukemia. Am. J. Med. Sci. (1904) 127:563-592.
2. KELLY E, RUSSELL SJ: History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. (2007) 15(4):651-659.
3. LIU TC, GALANlS E, KIRN D: Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. (2007) 4(2):101-117.
4. VAHA-KOSKELA MJ, HEIKKILA JE, HINKKANEN AE: Oncolytic viruses in cancer therapy. Cancer Lett. (2007).
5. WOO CY, OSADA T, CLAY TM, LYERLY HK, MORSE MA: Recent clinical progress in virus-based therapies for cancer. Expert Opin. Biol. Ther. (2006) 6(11):1123-1134.
6. WOO Y, ADUSUMlLLI PS, FONG Y: Advances in oncolytic viral therapy. Curr. Opin. Investig. Drugs (2006) 7(6):549-559.
7. CHERNAJOVSKY Y, LAYWARD L, LEMOINE N: Fighting cancer with oncolytic viruses. BMJ (2006) 332(7534):170-172.
8. THORNE SH, BARTLETT DL, KIRN DH: The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr. Gene Ther. (2005) 5(4):429-443.
9. STANFORD MM, MCFADDEN G, KARUPIAH G, CHAUDHRI G: Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol. Cell Biol. (2007) 85(2):93-102.
10. RAHAUS M, DESLOGES N, WOLFF MH: Varicella-zoster virus requires a functional P13K/Akt/GSK-3α/β signaling cascade for efficient replication. Cell Signal. (2007) 19(2):312-320.
11. ENJUANES L, ALMAZAN F, SOLA I, ZUNIGA S: Biochemical aspects of coronavirus replication and virus-host interaction. Annu. Rev. Microbiol. (2006) 60:211-230.
12. SALSMAN J, TOP D, BOUTILIER J, DUNCAN R: Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability. J. Virol. (2005) 79(13):8090-8100.
13. KAZEMI S, PAPADOPOULOU S, LI S et al.: Control of α subunit of eukaryotic translation initiation factor 2 (eIF2 α) phosphorylation by the human papillomavirus type 18 E6 oncoprotein: implications for eIF2 α-dependent gene expression and cell death. Mol. Cell Biol. (2004) 24(8):3415-3429.
14. CASTEDO M, ROUMIER T, BLANCO J et al.: Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J. (2002) 21(15):4070-4080.
15. NICHOLSON KM, ANDERSON NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. (2002) 14(5):381-395.
16. SCHMELZLE T, HALL MN: TOR, a central controller of cell growth. Cell (2000) 103(2):253-262.
17. BELL JC: Oncolytic viruses: what's next? Curr. Cancer Drug Targets (2007) 7(2):127-131.
18. KASUYA H, TAKEDA S, SHIMOYAMA S et al.: Oncolytic virus therapy - foreword. Curr. Cancer Drug Targets (2007) 7(2):123-125.
19. ROBERTS MS, LORENCE RM, GROENE WS, BAMAT MK: Naturally oncolytic viruses. Curr. Opin. Mol. Ther. (2006) 8(4):314-321.
20. KIRN D: Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene (2000) 19(56):6660-6669.
21. HEISE C, SAMPSON-JOHANNES A, WILLIAMS A et al.: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. (1997) 3(6):639-645.
22. ROGULSKI KR, FREYTAG SO, ZHANG K et al.: In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. (2000) 60(5):1193-1196.
23. RIES SJ: Elucidation of the molecular mechanism underlying tumor-selective replication of the oncolytic adenovirus mutant ONYX-015. Future Oncol. (2005) 1(6):763-766.
24. O SHEA CC, JOHNSON L, BAGUS B et al.: Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 6(6):611-623.
25. HECHT JR, BEDFORD R, ABBRUZZESE JL et al.: A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. (2003) 9(2):555-561.
26. MAKOWER D, ROZENBLIT A, KAUFMAN H et al.: Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res. (2003) 9(2):693-702.
27. MULVIHILL S, WARREN R, VENOOK A et al.: Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Ther. (2001) 8(4):308-315.
28. NEMUNAITIS J, CUNNINGHAM C, BUCHANAN A et al.: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. (2001) 8(10):746-759.
29. GARBER K: China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. (2006) 98(5):298-300.
30. LIU TC, KIRN D: Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res. (2007) 67(2):429-432.
31. FIGOVA K, HRABETA J, ECKSCHLAGER T: Reovirus - possible therapy of cancer. Neoplasma (2006) 53(6):457-462.
32. AGHI M, MARTUZA RL: Oncolytic viral therapies - the clinical experience. Oncogene (2005) 24(52):7802-7816.
33. BELL JC, LICHTY B, STOJDL D: Getting oncolytic virus therapies off the ground. Cancer Cell (2003) 4(1):7-11.
34. THORNE SH, HWANG TH, KIRN DH: Vaccinia virus and oncolytic virotherapy of cancer. Curr. Opin. Mol. Ther. (2005) 7(4):359-365.
35. SHEN Y, NEMUNAITIS J: Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol. Ther. (2005) 11(2):180-195.
36. WHITMAN ED, TSUNG K, PAXSON J, NORTON JA: In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery (1994) 116(2):183-188.
37. MCCART JA, WARD JM, LEE J et al.: Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. (2001) 61(24):8751-8757.
38. PUHLMANN M, BROWN CK, GNANT M et al.: Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. (2000) 7(1):66-73.
39. MOSS B, CARROLL MW, WYATT LS et al.: Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. (1996) 397:7-13.
40. ZEH HJ, BARTLETT DL: Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther. (2002) 9(12):1001-1012.
41. BULLER RM, CHAKRABARTI S, COOPER JA, TWARDZIK DR, MOSS B: Deletion of the vaccinia virus growth factor gene reduces virus virulence. J. Virol. (1988) 62(3):866-874.
42. BULLER RM, CHAKRABARTI S, MOSS B, FREDRICKSON T: Cell proliferative response to vaccinia virus is mediated by VGF. Virology (1988) 164(1):182-192.
43. GUO ZS, BARTLETT DL: Vaccinia as a vector for gene delivery. Expert Opin. Biol. Ther. (2004) 4(6):901-917.
44. GUO ZS, NAIK A, O MALLEY ME et al.: The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res. (2005) 65(21):9991-9998.
45. YANG S, GUO ZS, O'MALLEY ME et al.: A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Gene Ther. (2007) 14(8):638-647.
46. MASTRANGELO MJ, LATTIME EC: Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther. (2002) 9(12):1013-1021.
47. MASTRANGELO MJ, MAGUIRE HC, LATTIME EC: Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv. Exp. Med. Biol. (2000) 465:391-400.
48. MASTRANGELO MJ, MAGUIRE HC Jr, EISENLOHR LC et al.: Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. (1999) 6(5):409-422.
49. KIM JH, OH JY, PARK BH et al.: Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. (2006) 14(3):361-370.
50. HU Y, LEE J, MCCART JA et al.: Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy. J. Virol. (2001) 75(21):10300-10308.
51. TAGAWA M, KAWAMURA K, SHIMOZATO O et al.: Virology- and immunology-based gene therapy for cancer. Cancer Immunol. Immunother. (2006) 55(11):1420-1425.
52. BEUKEMA EL, BROWN MP, HAYBALL JD: The potential role of fowlpox virus in rational vaccine design. Expert Rev. Vaccines (2006) 5(4):565-577.
53. PETRULIO CA, KAUFMAN HL: Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev. Vaccines (2006) 5(1):9-19.
54. ARLEN PM, GULLEY JL: Therapeutic vaccines for prostate cancer: a review of clinical data. Curr. Opin. Investig. Drugs (2005) 6(6):592-596.
55. SKINNER MA, LAIDLAW SM, ELDAGHAYES I, KAISER P, COTTINGHAM MG: Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev. Vaccines (2005) 4(1):63-76.
56. HWANG C, SANDA MG: Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Curr. Opin. Mol. Ther. (1999) 1(4):471-479.
57. TARTAGLIA J, PINCUS S, PAOLETTI E: Poxvirus-based vectors as vaccine candidates. Crit. Rev. Immunol. (1990) 10(1):13-30.
58. FENNER F, RATCLIFFE FN: Myxomatosis. Cambridge University Press, Cambridge, UK (1965).
59. FENNER F: Adventures with poxviruses of vertebrates. FEMS Microbiol. Rev. (2000) 24(2):123-133.
60. STANFORD MM, WERDEN SJ, MCFADDEN G: Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet. Res. (2007) 38(2):299-318.
61. ZUNIGA MC: A pox on thee! Manipulation of the host immune system by myxoma virus and implications for viral-host co-adaptation. Virus Res. (2002) 88(1-2): 17-33.
62. KERR P, MCFADDEN G: Immune responses to myxoma virus. Viral Immunol. (2002) 15(2):229-246.
63. BARRETT JW, CAO JX, HOTA-MITCHELL S, MCFADDEN G: Immunomodulatory proteins of myxoma virus. Semin. Immunol. (2001) 13(1):73-84.
64. ANDREWES CH, HARISIJADES S: Propagation of myxoma virus in one-day old mice. Br. J. Exp. Pathol. (1955) 36(1):18-21.
65. MCCABE VJ, TARPEY I, SPIBEY N: Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein. Vaccine (2002) 20(19-20):2454-2462.
66. MCFADDEN G: Poxvirus tropism. Nat. Rev. Microbiol. (2005) 3(3):201-213.
67. WANG F, MA Y, BARRETT JW et al.: Disruption of Erk-dependent type I IFN induction breaks the myxoma virus species barrier. Nat. Immunol. (2004) 5(12):1266-1274.
68. SYPULA J, WANG F, MA Y, BELL JC, MCFADDEN G: Myxoma virus tropism in human tumor cells. Gene Ther. Mol. Biol. (2004) 8:108-114.
69. LUN X, YANG W, ALAIN T et al.: Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. (2005) 65(21):9982-9990.
70. MOSSMAN K, LEE SF, BARRY M, BOSHKOV L, MCFADDEN G: Disruption of M-T5, a novel myxoma virus gene member of poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits. J. Virol. (1996) 70(7):4394-4410.
71. JOHNSTON JB, WANG G, BARRETT JW et al.: Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1. J. Virol. (2005) 79(16):10750-10763.
72. WANG G, BARRETT JW, STANFORD M et al.: Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc. Natl. Acad. Sci. USA (2006) 103(12):4640-4645.
73. HAAS-KOGAN D, SHALEV N, WONG M et al.: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. (1998) 8(21):1195-1198.
74. DAHIA PL, AGUIAR RC, ALBERTA J et al.: PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum. Mol. Genet. (1999) 8(2):185-193.
75. AMORNPHIMOLTHAM P, SRIURANPONG V, PATEL V et al.: Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin. Cancer Res. (2004) 10(12 Part 1):4029-4037.
76. CHEN YL, LAW PY, LOH HH: Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr. Med. Chem. Anticancer Agents (2005) 5(6):575-589.
77. CHOW LM, BAKER SJ: PTEN function in normal and neoplastic growth. Cancer Lett. (2006).
78. PEDRERO JM, CARRACEDO DG, PINTO CM et al.: Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer (2005) 114(2):242-248.
79. HYUN T, YAM A, PECE S et al.: Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood (2000) 96(10):3560-3568.
80. STILES B, GILMAN V, KHANZENZON N et al.: Essential role of AKT-1/protein kinase Bα in PTEN-controlled tumorigenesis. Mol. Cell Biol. (2002) 22(11):3842-3851.
81. GEORGAKIS GV, YOUNES A: From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev. Anticancer Ther. (2006) 6(1):131-140.
82. STANFORD MM, BARRETT JW, NAZARIAN SH, WERDEN S, MCFADDEN G: Oncolytic virotherapy synergism with signaling inhibitors: rapamycin increases myxoma virus tropism for human tumor cells. J. Virol. (2007) 81(3):1251-1260.
83. DUNN C, CROOM KF: Everolimus: a review of its use in renal and cardiac transplantation. Drugs (2006) 66(4):547-570.
84. MARTY FM, BRYAR J, BROWNE SK et al.: Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood (2007) 110(2):490-500.
85. WEBSTER AC, LEE VW, CHAPMAN JR, CRAIG JC: Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation (2006) 81(9):1234-1248.
86. JOHNSTON JB, MCFADDEN G: Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol. (2004) 6(8):695-705.
87. BARRETT JW, SHUN CHANG C, WANG G et al.: Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells. Virology (2006).
88. BEDARD EL, JIANG J, ARP J et al.: Prevention of chronic renal allograft rejection by SERP-1 protein. Transplantation (2006) 81(6):908-914.
89. LUCAS A, MCFADDEN G: Secreted immunomodulatory viral proteins as novel biotherapeutics. J. Immunol. (2004) 173(8):4765-4774.
90. DAI E, GUAN H, LIU L et al.: Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J. Biol. Chem. (2003) 278(20):18563-18572.
91. NASH P, LUCAS A, MCFADDEN G: SERP-1, a poxvirus-encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection. Adv. Exp. Med. Biol. (1997) 425:195-205.
92. MOSSMAN K, NATION P, MACEN J et al.: Myxoma virus M-T7, a secreted homolog of the IFN-γ receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. Virology (1996) 215(1):17-30.
93. BEDARD EL, KIM P, JIANG J et al.: Chemokine-binding viral protein M-T7 prevents chronic rejection in rat renal allografts. Transplantation (2003) 76(1):249-252.
94. LIU L, LALANI A, DAI E et al.: The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimai hyperplasia after vascular injury. J. Clin. Invest. (2000) 105(11):1613-1621.
95. GRAHAM KA, LALANI AS, MACEN JL et al.: The T1/35 kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues. Virology (1997) 229(1):12-24.
96. POWER AT, BELL JC: Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol. Ther. (2007) 15(4):660-665.
97. POWER AT, WANG J, FALLS TJ et al.: Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. (2007) 15(1):123-130.
98. THORNE SH: Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors. Expert Opin. Biol. Ther. (2007) 7(1):41-51.
99. GILBERT P-A, MCFADDEN G: Poxvirus cancer therapy. Recent Patents Antiinfect. Drug Discov. (2006) 1:309-321.
100. MCKEE TD, GRANDI P, MOK W et al.: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. (2006) 66(5):2509-2513.
101. GANESH S, GONZALEZ EDICK M, IDAMAKANTI N et al.: Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. (2007) 67(9):4399-4407.
102. KIM JH, LEE YS, KIM H et al.: Relaxin expression from tumor-targeting adenoviruses and its mtratumoral spread, apoptosis induction, and efficacy. J. Natl. Cancer Inst. (2006) 98(20):1482-1493.